
THE NUMBER €1 billion.That is what Plural raised across two new funds, its largest haul yet. Plural said its 2024 raise, €500 million, was half that size. Partners said about a third of the new money went to an opportunities fund. That fund backs later rounds in companies Plural already owns a piece of. A third of the new pool is set aside for names the firm already knows.
PREMIER FEATURE The man who called the SpaceX IPO almost to the exact day says Elon is about to spend his $2.1 trillion war chest on three publicly traded companies. Discover More About Elon's "Hit List"
THE SETUP - Nvidia (NVDA) reports after the close. It fell about 4% Monday and was little changed before dawn. The S&P 500 lost about 1.9% Monday, and its futures were down about 0.2%.
- Commerce posted a rule that would require licenses for chips sent to some data centers. It targets sites that give firms based in China or Macau access to large blocks of computing. It is not in force yet.
- The 10-year yield was near 5.12%. October retail sales land at 8:30 a.m. Futures still price a quarter-point December rate hike.
PMD Signal Tracker 
IN FOCUS Blackstone Will Pay for Trials of a Drug J&J Is Buying. It Gets Royalties, Not Shares.Johnson & Johnson (JNJ) confirmed Monday it will buy Ollin Biosciences for $2.2 billion upfront. It may pay up to about $1.125 billion more in milestones. Ollin is private. Its lead drug, OLN324, targets two eye diseases. Blackstone Life Sciences, part of Blackstone (BX), will fund the drug's Phase 3 program. It will pay $750 million over several years. In return, it gets milestone payments and single-digit royalties. Its deal depends on J&J closing the purchase, which J&J expects by year-end. The structure appears to shift part of the trial's cost and risk off J&J's books. Blackstone would take on drug risk late, alongside a large buyer that has agreed to pay up for the asset. J&J shares fell about 1.1% Monday, less than the market. Late-Stage Money Wants a Buyer First For life science funds, this is a way into big drug pipelines without owning a company. The return is at risk, since royalties pay only if the drug is approved and sells. Our read is that private funds pay for trials more readily once a large buyer has signed. The deal's close, then the Phase 3 results, would test that read.
SIGNALS IN MOTION SIGNAL 1: Canaccord's CEO Bid for His Own Firm. His Offer Hinges on a Sale Already Signed.Canaccord Genuity agreed late Sunday to sell its UK wealth arm to a venture of Centerbridge and Mubadala. The deal gives that unit an enterprise value of about £1.17 billion. Canaccord expects to get about £564 million. Chief executive Dan Daviau then offered to take the whole firm private at about C$15.27 a share. That is C$7.45 in cash plus £4.15. His offer goes ahead only if the UK sale closes. Holders of about 35% back it. Canaccord closed Monday at C$14.89. The bid is about 27% above the Feb. 13 close. It is about 8% above the 30-day average price. A majority-of-minority vote is required. WHAT RESOLVES THIS For wealth-firm investors, this is a CEO bid that appears to pass the UK sale cash through to holders. At Monday's close, the stock sat about 2.5% below the offer's value at current exchange rates. Both deals aim to close in the first half of 2027. A rival bid before the go-shop ends Dec. 30, or the minority's vote, would settle the price. SIGNAL 2: Ares Is Leading a Loan That Lets a Buyout Owner Pay Itself.Ares Management (ARES) is leading a private loan to Scholt Energy, PitchBook reported. The loan is about €475 million. Scholt is owned by the buyout firm Waterland. The loan refinances existing debt and funds a dividend to the owner. The size of the dividend has not been disclosed. Neither has the loan's leverage. The owner gets cash without selling. Part of the loan pays off Scholt's existing debt. WHAT RESOLVES THIS For private credit funds, this is a loan to a firm the owner already holds, not a new buyout. What is at risk is the extra debt, since the payout is made with borrowed cash. Dividend deals like this tend to appear when lenders compete for deals. Final terms, including the margin and any disclosed leverage, would show whether lenders stretched to win it. SIGNAL 3: Watami's Founder Is Taking the Company Private. Two Banks Are Lending Against the Shares.Watami's founder plans to take the company private through a tender offer. The price is ¥1,284 a share. The board backs it. Founder Miki Watanabe's asset firm already holds 28.57%. The deal totals about ¥32 billion. The price is about 50% above the Nov. 12 close. Bank of Yokohama and Sumitomo Mitsui are lending, with the shares pledged as collateral. Suntory owns 13.52% and will not tender. It will swap its stake for non-voting shares in the bidder instead. WHAT RESOLVES THIS For Japan buyout investors, the bidder is the company's founder. Outside holders have their exit price at stake. The offer has no majority-of-minority condition to protect them. It needs at least 28.78% tendered by Dec. 28, and the count against that bar will settle it.
PARTNER SPOTLIGHT Wall Street veteran goes ALL in on Bank of Elon
A 20-year Wall Street veteran – who worked at a $10 billion hedge fund – is putting ALL his money in Elon Musk's new bank. He says he can see the writing on the wall for traditional banks. And he's not the only one. See if you should join him here (not just for the 6% yield). This ad is sent on behalf of InvestorPlace Media at 1125 N. Charles Street, Baltimore, Maryland 21201. If you're not interested in this opportunity, please click here.
WHAT MOST WILL MISS - Zelle picked Solana to carry its stablecoin abroad. The first route, from the U.S. to India, is targeted for the end of 2026. Zelle is owned by big U.S. banks. Its demo ran on a test network, and it gave no date for a live launch.
- On Kalshi, bets on a December hike bigger than a quarter point were at 6 cents early Tuesday, down from 9 cents Monday morning. Bitcoin was near $64,600 early Tuesday.
THE CROSSOVER Private Market Trends Driving Public Market MovesPrivate Checks Went to Known Bets. Public Buyers Get Their Turn Wednesday. Private money went where it already had an edge. Plural kept a third of its new funds for companies it backs. Blackstone would fund a trial alongside J&J's deal to buy the drug. Canaccord's CEO and Watami's founder are bidding for firms they know well. Public buyers face a different test. Nvidia reports tonight. Anthropic has said it expects to price its IPO Wednesday. Our read is that private money pays up most where it has inside knowledge or a buyer lined up. Where Anthropic prices against its $70 to $78 range would show whether public buyers still pay up without that edge. On the calendar... When | Event | Tue., Nov. 17 | Retail sales, 8:30 a.m.; Nvidia reports after the close | Wed., Nov. 18 | Fed minutes, 2 p.m. Anthropic pricing expected, per the company | Thu., Nov. 19 | Anthropic expected to begin trading, per the company | Tue.-Wed., Dec. 8-9 | Fed meeting |
AI Moves Into the Biotech LabFor most of the AI boom, the money followed the hardware. Chips. Data centers. Cloud. Now the algorithms are walking into the lab. In September, a drug whose target was found by AI, and whose molecule was designed by AI, dosed its first patient in a Phase III trial. A second AI-engineered medicine is in Phase III too. We profiled the 5 companies leading the shift in a new FREE Special Report: AI Moves Into the Biotech Lab. We'll text it straight to your phone. Get the Free Report by Text → |